JPRN-UMIN000008632
Recruiting
Phase 2
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer - Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine0 sites35 target enrollmentAugust 6, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Advanced or recurrent gastric cancer previously treated with S-1
- Sponsor
- Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Drug hypersensitivity. 2\) Infection and inflammation. 3\) Prior infusion of paclitaxel 4\) Peripheral neuropathy 5\) Active synchronous malignancy. 6\) Brain metastasis. 7\) Severe mental disorders. 8\) Symptomatic pulmonary fibrosis or interstitial pneumonia. 9\) Severe systemic edema. 10\) A large amount of pleural effusion or peritoneal fluid. 11\) Severe heart disease. 12\) Myocardial infarction within six months. 13\) DM with insulin injection. 14\) Pregnant patient
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Phase II Study of Paclitaxel in Combination with Carboplatin in Patients With Stage IB-II Cervical Cancer.cervical cancerJPRN-UMIN000012400Department of Obstetrics and Gynecology, Osaka Medical College30
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
Completed
Phase 2
Phase II trial of Combination with Paclitaxel, Carboplatin and Cetuximab (PCE) as a first line treatment in patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckJPRN-UMIN000010507CSPOR-HN 02 executive committee45
Active, not recruiting
Phase 1
A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancerAdvanced, recurrent epithelial ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2006-007013-20-DKOnkologisk afdeling R and the Unit for Experimental Chemotherapy70
Completed
Phase 2
A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast CancerJPRN-UMIN000008140Kobe Breast Cancer Oncology Group24